Small Molecule Pcsk9 Inhibitors
Tech ID: 34403 / UC Case 2023-098-0
Technology Description
Therapeutic inhibition of PCSK9 lowers LDL cholesterol and reduces the risk of heart disease, even when added on top of maximum dose statin therapy. However, there are currently no FDA approved small molecule inhibitors for PCSK9. UCSF scientists engineered a cell-based, amplified readout of PCSK9 protease activity and translated this into a high-throughput screen. They have identified small molecules that bind to and allosterically affect PCSK9 processing, and upregulate the LDL receptor in model cell cultures, and which could be attractive therapies for further cholesterol lowering and the prevention of atherosclerosis.
Stage of Development
proof of concept
Patent Status
Patent Pending
Contact
- Catherine Smith
- Catherine.Smith2@ucsf.edu
- tel: View Phone Number.
